For this reason, many therapeutic agents that directly target MYC are under development; however, to date, their clinical efficacy remains to be demonstrated partially due to the extreme difficulty of developing efficient MYC inhibitors specifically targeted for cancer therapy [15,83]. This evidence concerns the gene MYC and cancer.